採用
必須スキル
Leadership
Market access
Payer relations
Strategic Planning
Negotiation
Communication
CRM systems
PowerPoint
Excel
Company Overview:
Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Position Overview:
We’re seeking a dynamic Head of Field Market Access tolead the field market access organization, calling on payers and Treatment Centers. The Senior Director, Field Market Access is a field-based strategic people leader responsible for driving appropriate access and coverage for Beam’s portfolio across payers and Gene Therapy Treatment Centers. This is a high-impact commercial leadership role at the forefront of transforming access to gene therapy for patients with sickle cell disease.
The Senior Director will lead a team responsible for developing and maintaining relationships with state Medicaid payers, national, and regional payers to ensure coverage and reimbursement for Beam’s therapies, including risto-cel. The ideal candidate will have a successful track record of people leadership of field market access teams, payer engagement and strategic account management. The position reports into the VP, Market Access and Public Policy.
Responsibilities And Duties:
-
Lead team responsible for all market access and reimbursement stakeholder field engagement for assigned accounts (payer and Treatment Center).
-
Serve as a subject matter expert on local payers (Medicaid and commercial), including payer needs, policy shifts, and contracting opportunities.
-
Support team in delivering compelling value propositions and payer materials customized to each stakeholder’s needs.
-
Help team build and execute account-specific business plans in alignment with Beam’s broader market access and brand strategies.
-
Partner cross-functionally with other field leadership, including Medical Science Liaisons and Key Account Management teams, especially for Treatment Center engagement.
-
Track and report market trends, competitive intelligence, policy changes, and access barriers across the commercial self-insured and Medicare landscapes.
-
Collaborate on the development of performance KPIs and metrics to evaluate access success and account performance.
Qualifications And Skills:
-
Bachelor's degree required; advanced degree preferred.
-
18+ years of progressive experience in the pharmaceutical or biotech industry with 10+ years in market access, including field and / or strategy roles.
-
5+ years of people leadership experience.
-
Rare disease or oncology experience required; buy & bill experience required.
-
Cell or Gene Therapy experience preferred.
Deep understanding of:
-
Commercial payers (national and regional) and approach to medical policy decision-making.
-
Medicaid policy development
-
CMS protocols and applications (NTAP, J-code, etc.)
-
Demonstrated success in building and managing relationships with payers and financial decision-makers in Treatment Centers.
-
Proven record of existing relationships with payers and financial decision-makers.
-
Strategic thinking with a collaborative mindset and ability to influence cross-functional teams, with unique persistence in driving patient access to complex medicines.
-
Excellent communication, presentation, and negotiation skills.
-
Proficiency with CRM systems, PowerPoint, and Excel.
-
Willingness to travel approximately 50% of the time/as needed.
The salary range below reflects the full-time base salary range we expect to pay for this role at the time of posting. Base pay will be determined based on several factors including, but not limited to, relevant experience, education, scope of job, internal comparisons, and market data.
Beam Pay Range**$260,000—$320,000 USD**
総閲覧数
1
応募クリック数
0
模擬応募者数
0
スクラップ
0
類似の求人

Pick Up & Delivery Supervisor
Old Dominion · Birmingham, AL

Shift Lead Saratoga Springs, Utah
Walgreens · saratoga springs

Code & AI Security Research Manager (Cortex Cloud) Tel Aviv, Tel Aviv 01/26/2026
Palo Alto Networks · tel aviv

Manager, Strategic Projects
Carnival · Miami, FL, United States, US

AI Platforms & Orchestration Lead
Paramount · Los Angeles, CA, US, 90038
Beam Therapeuticsについて

Beam Therapeutics
PublicBeam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts.
201-500
従業員数
Cambridge
本社所在地
$1.3B
企業価値
レビュー
2.0
1件のレビュー
ワークライフバランス
2.0
報酬
3.0
企業文化
1.5
キャリア
2.0
経営陣
1.0
15%
友人に勧める
良い点
Competitive compensation
Steady paycheck
Regular pay
改善点
Micromanagement
Lack of hybrid work options
Poor leadership behavior
給与レンジ
52件のデータ
Junior/L3
Mid/L4
Senior/L5
Staff/L6
Intern
Director
Junior/L3 · Manufacturing Associate I
1件のレポート
$71,300
年収総額
基本給
$62,000
ストック
-
ボーナス
-
$71,300
$71,300
面接体験
64件の面接
難易度
3.4
/ 5
期間
14-28週間
内定率
37%
体験
ポジティブ 64%
普通 19%
ネガティブ 17%
面接プロセス
1
Phone Screen
2
Technical Interview
3
System Design
4
Behavioral
5
Team Fit
よくある質問
Tell me about a challenging project
System design question
Coding problem
Why this company
ニュース&話題
Executive pay and board elections at Beam Therapeutics (NASDAQ: BEAM) 2026 virtual meeting - Stock Titan
Stock Titan
News
·
4d ago
Buy Signal Beam Therapeutics Inc - 16 Apr 2026 @ 09:41 -> USD30.18
Ticker: **BEAM** Exchange: **NASDAQ** Time: **16 Apr 2026 @ 09:41** Price: **USD30.18** Link: https://getagraph.com/NASDAQ/stock/live-signals/BEAM/ENG
·
5d ago
·
1
Beam Therapeutics (BEAM) Is Up 20.6% After Positive Gene-Editing Data And New Credit Facility - Has The Bull Case Changed? - Yahoo Finance
Yahoo Finance
News
·
5d ago
BEAM SEC Filings - Beam Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Stock Titan
News
·
5d ago